Mesothelin (MSLN) promotes the level and activation of MET through the JNK signaling pathway, enabling cancer cells to disrupt tight junctions and the integrity of the blood-brain barrier (BBB), thus penetrating the barrier (Xia et al., 2024). Here, MET is linked to cancer.